Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

MAPK Pathway

Chemical Structure Cat. No. Product Name CAS No.
MNK1/2-IN-5 Chemical Structure
BCP46296 MNK1/2-IN-5 1426928-20-2
MNK1/2-IN-5 is a potent and selective MNK1/2 inhibitor as a therapeutic agent.
SB-747651A Chemical Structure
BCP46274 SB-747651A 607372-46-3
SB-747651A is a specific mitogen- and stress-activated kinase 1 (MSK1) inhibitor. SB-747651A can be used for the research of inflammation.
SB-747651A dihydrochloride Chemical Structure
BCP46273 SB-747651A dihydrochloride 1781882-72-1
SB-747651A dihydrochloride is a potent MSK1 inhibitor; also inhibiting other AGC group kinases.
Zunsemetinib Chemical Structure
BCP43532 Zunsemetinib 1640282-42-3
Zunsemetinib, also knoiwn as ATI-450 and CDD450, is a potent MK2 Inhibitor. ATI-450 binds with high affinity to the interface of the p38MAPK-MK2 complex and selectively inhibits p38MAPK-catalysed phosphorylation of MK2 which stabilises the inactive conformation of MK2, and subsequently reduces inflammatory cytokine levels. ATI-450 specifically blocks the downstream MK2-mediated inflammatory drive on the p38 pathway and may therefore avoid the tachyphylaxis associated with p38 inhibitors.
PF-05381941 Chemical Structure
BCP45842 PF-05381941 1474022-02-0
PF-05381941 is a novel potent dual TAK1/p38a inhibitor.
CMPD-1 Chemical Structure
BCP45765 CMPD-1 41179-33-3
CMPD-1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM.
MK-2 Inhibitor III H2O Chemical Structure
BCP44458 MK-2 Inhibitor III H2O 1186648-22-5
MK2-IN-3 hydrate is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.
Encorafenib Chemical Structure
BCP44104 Encorafenib 1269440-29-0
Encorafenib is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells.
Rineterkib hydrochloride Chemical Structure
BCP43938 Rineterkib hydrochloride 1715025-34-5
Rineterkib is a RAF and ERK1/2 inhibitor which has demonstrated preclinical activity in multiple MAPK activated cancer cells and xenograft models.
Indirubin-3'-oxime Chemical Structure
BCP43705 Indirubin-3'-oxime 667463-82-3
Indirubin-3'-monoxime, a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.
123下一页末页共 239 条记录 1 / 24 页